Compound research hub
Ipamorelin: Research, Handling and Batch Documentation
Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide agonist at the growth hormone secretagogue receptor, GHS-R1a.
Part of Volta's peptides.
Identity and specification
- Form
- Lyophilized powder
- Appearance
- White lyophilised powder
- Compound class
- Growth hormone secretagogue receptor (GHS-R1a) agonist
- CAS number
- 170851-70-4
- Molecular formula
- C₃₈H₄₉N₉O₅
- Molecular weight
- 711.85 g/mol
- PubChem CID
- 9831659
- Production
- Synthetic, by solid-phase peptide synthesis
- Solubility
- Soluble in sterile water
- Shelf life
- 24 months from date of manufacture
Molecular structure, sequence and the published laboratory studies on Ipamorelin are in the compound library entry for Ipamorelin.
Vial sizes available
Every size of Ipamorelin Volta lists, in stock or not. Each is a separate catalogue page with its own batch number and specification table.
- In stock
Ipamorelin 5mg 5mgBatch #: VPIP5100 - Restocking
Ipamorelin 10mg 10mgBatch #: VPIP10100
Purity and batch documentation
Volta's release specification is >99% (HPLC). That is a threshold we set. >99% is the specification every batch is released to. The figure on a certificate is what a laboratory measured for one lot.
SideChain Analytics reported 99.5% by HPLC-MS/MS on September 27, 2026, lot VPIP5100.
Covers the Ipamorelin 5mg vial.
Research on Ipamorelin
Handling and stability
Laboratory guides
Regulatory context
Ipamorelin in Canada
Ipamorelin is not authorized for sale in Canada or anywhere else. No regulator has approved it for any indication, and no approved ipamorelin product exists.
- Health Canada has issued no Notice of Compliance and no Drug Identification Number (DIN) for ipamorelin. There is no authorized product and no pharmacy stocks it.
- It is unapproved in every major jurisdiction, including the United States, the United Kingdom and the European Union, and is Schedule 4 under the TGA in Australia.
- Clinical development was discontinued, so there is no pending submission and no expected approval date to quote.
- Volta supplies ipamorelin for in-vitro laboratory research only. It is not a medicine, is not dispensed against a prescription, and is not authorised for human use.
- Is ipamorelin approved in Canada?
- No. Health Canada has not authorized ipamorelin for any indication. There is no Notice of Compliance and no DIN, so it cannot lawfully be sold as a medicine in Canada and is not stocked by Canadian pharmacies.
- Will ipamorelin be approved in Canada?
- There is no basis for a date. Clinical development of ipamorelin was discontinued, so no regulatory submission is pending with Health Canada or any other regulator, and there is no expected approval timeline to report.
- Can you buy ipamorelin in Canada in 2026?
- Not as a medicine. No authorized ipamorelin product exists, so there is nothing a pharmacy can dispense and no prescription that can be written for it. What is sold is research material rather than an approved drug, supplied for in-vitro laboratory use only.
Regulatory position verified 2026-10-10. Positions change; this page states the date it was last checked rather than implying it is current.
More peptides
Ipamorelin sits in Volta's peptides group, alongside the other compounds of the same composition. The whole range is on the full research catalogue, and the library of comparisons and guides is under peptide research.